• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Certification, Purchasing and Quality Assurance

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Cosmetics
  • CSAR China cosmetics infringements lead to suspension of lavender essential oil production

CSAR China cosmetics infringements lead to suspension of lavender essential oil production

CSAR China cosmetics infringements
Thursday, 26 May 2022 / Published in Cosmetics, News, NMPA Registration in China

CSAR China cosmetics infringements lead to suspension of lavender essential oil production

CSAR China cosmetics regulations are being increasingly enforced by the NMPA (National Medical Products Administration). This is leading to the increased identification of infringements of the CSAR (Cosmetics Supervision and Administration Regulations) as witnessed recently with the suspension of production of lavender essential oil by the manufacturer Jian Shan Lake.

On April 15, 2022, China’s NMPA announced on behalf of the Anhui Medical Products Administration (MPA) that it is suspending Jian Shan Lake’s production of lavender essential oil (No.1-3-2022).  

The reason for the suspension is that the essential oil contains 2.5% “vanilla butyl ether” in its product formula which exceeds the 1.5% allowed according to the IECIC (Existing Cosmetic Ingredients in China) 2021. Exceeding 1.5% is considered harmful to human health as well as imposing safety risks.

Suspending production can be enforced under the CSAR when production can cause human injury or cause potential health risks. This is specified in Article 54 of the Cosmetics Supervision and Administration Regulations, namely:

“all business operations and production related to the cosmetics product, either causing human injury or with evidence indicating potential health risks on human beings, can be suspended immediately by the responsible department under the NMPA”.

CSAR China cosmetics infringements – How to avoid

Observing CSAR requirements for product formulas is vital to avoid suspension of the production, marketing, or sale of cosmetics in China. Applicants should ensure the content of raw materials used in cosmetics comply with the Chinese regulations as the product formula is a key component of the filing and registration of a cosmetic product in China.

In cases of suspension, the manufacturer can apply to the relevant MPA or the NMPA for administrative reconsideration within 60 days. Another option is to file an administrative lawsuit with the local court within 6 months.

At Cisema, we can assist you with ensuring that your company meets the latest product quality and safety requirements in China. We act as an NMPA Domestic Responsible Agent for cosmetics manufacturers and cosmetic ingredient suppliers worldwide.  

Cisema covers all your needs from registration to post-market compliance to in-China OEM and subsidiary localization.

Send us your enquiry to see how we can help you.

By Jeff Jiang.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers

What you can read next

china clinical application management
China Clinical Application Management on Restrictive Medical Technologies – Catalogue and Specifications (2022 Edition)
Definition of Drug/Device Combination Products
New NMPA Classification Catalogue for Medical Devices

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
  • Publications
  • Seminars
  • Webinars

Recent Posts

  • clinical trials locally applied locally acting products

    New Guidelines on Clinical Trials of Locally Applied, Locally Acting Products

    Guidelines for clinical trials of locally appli...
  • medical device naming rules china

    China Medical Device Naming Rules Updated

    Medical device naming rules for China have been...
  • medical device qms audit

    Medical device QMS audit guidelines for product registration are open for comment

    China’s NMPA has issued draft guidelines on med...
  • china compulsory certificate

    Cisema Webinar: Certification in China – China Compulsory Certificate (CCC)

    The China Compulsory Certificate (CCC) is a man...
  • china gmp for pharmaceutical packaging

    China GMP for Pharmaceutical Packaging Materials (Draft for comments)

    A China Good Manufacturing Practices (GMP) on P...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.